Regarding toxicity, the combined therapeutic use of bisphosphonate and IL-2 has been used with modest success in cancer patients to promote the in vivo expansion of γδ T cells, with relatively minor adverse effects, including fever, injection site soreness, nausea, and diarrhea, being reported [113]. The gene discussed is IL2; the disease is cancer.